Because aspirin can inhibit NF-κB activity (46, 47), we speculate that aspirin may reduce the risk of severe CRS in patients with mild COVID-19 by inhibiting the activity of NF-κB. This evidence concerns the gene NFKB1 and congenital rubella syndrome.